全文获取类型
收费全文 | 48163篇 |
免费 | 4719篇 |
国内免费 | 61篇 |
专业分类
耳鼻咽喉 | 373篇 |
儿科学 | 1430篇 |
妇产科学 | 1119篇 |
基础医学 | 6534篇 |
口腔科学 | 834篇 |
临床医学 | 5707篇 |
内科学 | 9378篇 |
皮肤病学 | 741篇 |
神经病学 | 4264篇 |
特种医学 | 1868篇 |
外国民族医学 | 3篇 |
外科学 | 7048篇 |
综合类 | 921篇 |
一般理论 | 59篇 |
预防医学 | 5223篇 |
眼科学 | 1157篇 |
药学 | 3375篇 |
中国医学 | 56篇 |
肿瘤学 | 2853篇 |
出版年
2023年 | 320篇 |
2022年 | 624篇 |
2021年 | 1390篇 |
2020年 | 711篇 |
2019年 | 1155篇 |
2018年 | 1286篇 |
2017年 | 903篇 |
2016年 | 978篇 |
2015年 | 1081篇 |
2014年 | 1510篇 |
2013年 | 1953篇 |
2012年 | 2938篇 |
2011年 | 2895篇 |
2010年 | 1606篇 |
2009年 | 1388篇 |
2008年 | 2363篇 |
2007年 | 2379篇 |
2006年 | 2239篇 |
2005年 | 2078篇 |
2004年 | 1965篇 |
2003年 | 1797篇 |
2002年 | 1627篇 |
2001年 | 1228篇 |
2000年 | 1238篇 |
1999年 | 1068篇 |
1998年 | 466篇 |
1997年 | 409篇 |
1996年 | 385篇 |
1995年 | 317篇 |
1994年 | 346篇 |
1993年 | 345篇 |
1992年 | 829篇 |
1991年 | 800篇 |
1990年 | 784篇 |
1989年 | 687篇 |
1988年 | 705篇 |
1987年 | 664篇 |
1986年 | 612篇 |
1985年 | 680篇 |
1984年 | 547篇 |
1983年 | 425篇 |
1982年 | 281篇 |
1981年 | 299篇 |
1980年 | 269篇 |
1979年 | 485篇 |
1978年 | 361篇 |
1976年 | 283篇 |
1974年 | 291篇 |
1973年 | 264篇 |
1972年 | 269篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Christopher Teng JiaDe Yu Jesse Taylor Adam I. Rubin James R. Treat 《Pediatric dermatology》2019,36(5):697-701
Erosive pustular dermatosis of the scalp (EPDS) is an uncommon chronic inflammatory response to scalp trauma that usually resolves with cicatricial alopecia. It most commonly affects elderly patients with a history of actinic damage. Herein, we describe a 16‐year‐old girl with acrofacial dysostosis type 1 presenting after surgery with crusting purulent scalp lesions, whose clinical presentation and histopathologic findings were consistent with EPDS. A review of the literature on EPDS in children is also detailed. 相似文献
6.
7.
8.
Anuj Shrestha Zeeshan Jawa Kathryn L. Koch Amy B. Rankin Qun Xiang Anand Padmanabhan Matthew S. Karafin Joshua J. Field 《Journal of clinical apheresis》2015,30(6):353-358
Red cell exchange (RCE) is a common procedure in adults with sickle cell disease (SCD). Implantable dual lumen Vortex (DLV) ports can be used for RCE in patients with poor peripheral venous access. We performed a retrospective cohort study of RCE procedures performed in adults with SCD. The main objective of the study was to compare the inlet speed, duration of procedures and rate of complications performed through DLV ports to those performed through temporary central venous and peripheral catheters. Twenty‐nine adults with SCD underwent a total of 318 RCE procedures. Twenty adults had DLV ports placed and 218 procedures were performed using DLV ports. Mean length of follow‐up after DLV port placement was 397 ± 263 days. Six DLV ports were removed due to infection and 1 for malfunction after a mean of 171 ± 120 days. Compared to temporary central venous and peripheral catheters, DLV port procedures had a greater rate of procedural complications, a longer duration, and a lower inlet speed (all P < 0.01). When accounting for the maximum allowable inlet speed to avoid citrate toxicity, 40% of DLV port procedures were greater than 10% below maximum speed, compared to 7 and 14% of procedures performed through temporary central venous and peripheral catheters (P < 0.0001). In conclusion, DLV ports can be used for RCE in adults with SCD, albeit with more procedural complications and longer duration. The smaller internal diameter and longer catheter of DLV ports compared to temporary central venous catheters likely accounts for the differences noted. J. Clin. Apheresis 30:353–358, 2015. © 2015 Wiley Periodicals, Inc. 相似文献
9.
10.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献